Highest-materiality recent filing
TransMedics appoints Fernando Araujo as CFO; reiterates FY26 revenue guidance of $737M-$757M
Fernando Araujo, ex-GE HealthCare CFO, becomes CFO and Treasurer effective Sept 21, 2026; succeeds Gerardo Hernandez.
TransMedics Q2 revenue up 21% to $189.9M; net income falls to $0.41 EPS; raises FY guidance low end
Total revenue $189.9M (+21% YoY); product revenue $111.2M (+16%), service revenue $78.8M (+29%).
TransMedics Q1 revenue up 21% but net income plunges 71% YoY; guidance reiterated
Revenue $173.9M (+21% YoY); net income $7.3M ($0.20 diluted EPS), down 71% from $0.70.
TransMedics provides tax valuation allowance impact: Q4 adjusted EPS $0.47
Released $103.3M U.S. tax valuation allowance in Q4, driving $83.8M net income tax benefit.
TransMedics Q4 revenue $160.8M (+32% YoY); net income $105.4M includes $83.8M tax benefit
Q4 revenue $160.8M (+32% YoY); full-year revenue $605.5M (+37% YoY).
TransMedics signs 498,286 sq ft HQ lease in Somerville, MA; buys two adjacent parcels for $30M
Lease for ~498,286 sq ft at 188 Assembly Park Drive, Somerville, MA; initial annual base rent of ~$23.9M with 2% annual escalations.
TransMedics Q3 revenue $143.8M (+32% YoY); raises FY2025 guidance to $595-605M
Revenue $143.8M, up 32% vs Q3 2024; net income $24.3M ($0.66 diluted EPS) vs $4.2M a year ago.
TransMedics Q2 revenue $157.4M (+38% YoY), net income $34.9M; raises FY2025 guidance
Revenue $157.4M vs $114.3M YoY (+38%); net income $34.9M ($0.92 diluted EPS) vs $12.2M.
TransMedics Q1 revenue $143.5M (+48% YoY), net income $25.7M; raises FY2025 guidance to $565-585M
Q1 revenue $143.5M (+48% YoY from $96.9M); net income $25.7M ($0.70 diluted EPS), up from $12.2M in Q1 2024.
TransMedics Q4 revenue $121.6M (+50% YoY); full year net income $35.5M; 2025 guidance $530-552M
Q4 revenue $121.6M (+50% YoY); net income $6.9M ($0.19 EPS); full year revenue $441.5M (+83% YoY).
TransMedics appoints Gerardo Hernandez as CFO; updates 2024 revenue guidance to $428M-$432M
Hernandez appointed CFO effective Dec 2, 2024, succeeding Stephen Gordon, who will remain as non-executive employee through Mar 2025 then senior advisor through Mar 2026.
TransMedics Q3 revenue $108.8M (+64% YoY), net income $4.2M; FY guidance reaffirmed
Total revenue $108.8M, up 64% from $66.4M in Q3 2023.
TransMedics Q2 revenue $114.3M (+118% YoY), net income $12.2M, raises FY guidance
Revenue $114.3M (+118% YoY); net income $12.2M ($0.35 diluted EPS) vs net loss $1.0M.
Q1 net revenue $96.9M (+133% YoY); net income $12.2M ($0.35 diluted EPS) vs net loss $2.6M in Q1 2023.
TransMedics Q4 revenue $81.2M (+159% YoY); guides FY2024 $360-370M
Q4 2023 revenue $81.2M (+159% YoY); net income $4.0M ($0.12 EPS) vs loss of $6.7M in Q4 2022.
TransMedics amends credit agreement for $300M acquisition capacity; buys 9th aircraft
Third amendment to CIBC credit agreement permits acquisitions up to $300M aggregate without further lender consent.
TransMedics Q3 revenue $66.4M (+159% YoY); raises FY2023 guidance to $222-230M
Revenue $66.4M, up 159% YoY; includes $2.1M from new aviation business and $1.6M non-recurring charter revenue.
TransMedics closes Summit Aviation acquisition to launch national organ transplant air logistics
Acquisition of Summit Aviation completed; creates TransMedics Aviation as first dedicated national organ transplant air logistics provider.
TransMedics Q2 revenue $52.5M, up 156% YoY; raises FY 2023 guidance to $180M-$190M
Net revenue $52.5M in Q2 2023, up 156% from $20.5M YoY; net loss narrowed to $1.0M from $11.5M.
Second Amendment to Credit Agreement with CIBC allows cash consideration up to $50M per acquisition, $150M total.
TransMedics issues $460M of 1.50% convertible notes due 2028; enters capped call transactions
Issued $460M aggregate principal of 1.50% Convertible Senior Notes due 2028, including full exercise of $60M greenshoe.
TransMedics amends credit agreement to allow up to $460M convertible notes and capped calls
On May 8, 2023, entered First Amendment to Credit Agreement with CIBC to enable 1.50% Convertible Senior Notes due 2028.
TransMedics Q1 revenue $41.6M (+162% YoY); raises FY23 guidance to $160-170M
Q1 2023 revenue $41.6M (+162% YoY from $15.9M) driven by NOP adoption and OCS Liver/Heart sales.
TransMedics Q4 revenue $31.4M (+225% YoY); guides FY2023 $138-145M
Total revenue $31.4M in Q4 2022, up 225% from $9.7M in Q4 2021; full-year revenue $93.5M (+209%).
TransMedics Q3 revenue $25.7M (+378% YoY); 2022 guidance raised to $80-85M
Net revenue $25.7M including $1.4M favorable adjustment; ex-adjustment $24.3M (+349% YoY).
Offering of 3,250,000 shares of common stock at $37.60 per share; overallotment option for 487,500 shares exercised in full.
TransMedics Q2 revenue up 151% to $20.5M, raises 2022 guidance to $67M-$75M
Net revenue $20.5M in Q2 2022 vs $8.2M a year ago (+151%); gross margin improved to 70% from 68%.
On September 10, 2026, the Board of Directors (the “Board”) of TransMedics Group, Inc. (the “Company”) appointed Fernando Araujo as Chief Financial Officer and Treasurer, effective as of September 21, 2026.
Max materiality 0.90 · Median 0.60 · Most common event earnings